CWP
NBIX icon

Curated Wealth Partners’s Neurocrine Biosciences NBIX Stock Holding History

Curated Wealth Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,671
Closed -$368K – 220
2024
Q1 		$368K Buy
+2,671
New +$365K 0.05% 104

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Curated Wealth Partners's NBIX Position: Q1 2025 in Review

Curated Wealth Partners sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 2,704 shares — an estimated $369K sold.

Curated Wealth Partners first reported a position in NBIX in Q3 2023 and held it in 5 quarters. The position peaked at $374K in Q4 2023. 588 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Curated Wealth Partners reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Curated Wealth Partners sold 2,704 Neurocrine Biosciences shares in Q1 2025, an estimated $369K.
  • Curated Wealth Partners first reported a position in Neurocrine Biosciences in Q3 2023 and held it in 5 quarters.
  • Curated Wealth Partners's Neurocrine Biosciences position peaked at $374K in Q4 2023.
  • 588 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Curated Wealth Partners's 13F filing for Q1 2025, filed 15 Apr 2025.